The purpose of the study is to find out is AUTX-007 an investigational drug, can help treat or cure cancer.

We are looking for a dose of the APVO436 in combination with venetoclax and azacitidine that can be administered safely to participants who have been diagnosed with AML.

Do you have sickle cell trait or wonder if you might? Join our study to learn more about how having sickle cell trait could impact your health. The study uses simple lab tests, and participants receive compensation.

Do you have an advanced cancer? Are you 60+ years old? If so, you may be able to take part in a study to understand how patients and doctors communicate when choosing treatments. Compensation provided.

Are you Black/African American or have Middle Eastern ancestry? Are you not taking any medicines that could change your blood count? If so, you might be able to join a study to find out the normal levels of a type of blood cell called neutrophils. Compensation provided.

Have you been diagnosed with Chronic Myeloid Leukemia, have a T315I mutation, and previously treated with at least two tyrosine kinase inhibitors (TKIs)? You might be able to participate in this study.

The purpose of this research study is to compare the effectiveness of two combinations of anticancer study drugs in treating your Chronic Lymphocytic Leukemia (CLL). The first combination is sonrotoclax (also known as BGB-11417) and zanubrutinib, while the second combination is venetoclax and obinutuzumab. The aim is to determine which combination of study drugs is more effective in controlling your specific type of cancer,

This study will evaluate the feasibility of using capillary blood samples collected with the Tasso device for analysis of CBC in diseased patients with leukemia, lymphoma, and/or other blood cell disorders.

Are you over 60 and were recently diagnosed with mantle cell lymphoma? You may be able to participate in a research study to determine whether patients who reach complete disease remission after treatment with rituximab and zanubrutinib, will remain longer in remission with or without continuous zanubrutinib treatment.

Do you have Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia? Are you looking for other treatment options? We are doing a study to find out whether treatment with the study drug (Bexmarilimab) along with standard treatment can help your cancer.